JO3683B1 - صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها - Google Patents

صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها

Info

Publication number
JO3683B1
JO3683B1 JOP/2016/0133A JOP20160133A JO3683B1 JO 3683 B1 JO3683 B1 JO 3683B1 JO P20160133 A JOP20160133 A JO P20160133A JO 3683 B1 JO3683 B1 JO 3683B1
Authority
JO
Jordan
Prior art keywords
solid formulation
oral solid
preparation
formulation containing
containing irinotecan
Prior art date
Application number
JOP/2016/0133A
Other languages
English (en)
Inventor
Il Kim Yong
Soo Woo Jong
Hyun Park Jae
Cheul Kim Jin
Ki Jung Myeong
Hyung Min Park Caleb
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of JO3683B1 publication Critical patent/JO3683B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

يتعلق الاختراع الحالي بصياغة صلبة عبر الفم تشتمل على إرينوتيكان أو ملح مقبول صيدلانياً منها على هيئة مكون فعّال، وعامل تحميض.
JOP/2016/0133A 2015-06-30 2016-06-28 صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها JO3683B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150093413A KR102293907B1 (ko) 2015-06-30 2015-06-30 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Publications (1)

Publication Number Publication Date
JO3683B1 true JO3683B1 (ar) 2020-08-27

Family

ID=57608859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0133A JO3683B1 (ar) 2015-06-30 2016-06-28 صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها

Country Status (30)

Country Link
US (2) US11090299B2 (ar)
EP (1) EP3300483B1 (ar)
JP (2) JP6835746B2 (ar)
KR (2) KR102293907B1 (ar)
CN (1) CN107949375B (ar)
AR (1) AR105203A1 (ar)
AU (2) AU2016286804B2 (ar)
BR (1) BR112017028468B1 (ar)
CA (1) CA2988079C (ar)
CL (1) CL2017003437A1 (ar)
CO (1) CO2017013317A2 (ar)
CR (1) CR20170604A (ar)
DO (1) DOP2017000307A (ar)
EC (1) ECSP17085443A (ar)
ES (1) ES2930663T3 (ar)
GT (1) GT201700280A (ar)
IL (1) IL256278B (ar)
JO (1) JO3683B1 (ar)
MX (2) MX381735B (ar)
MY (1) MY191297A (ar)
PE (1) PE20181040A1 (ar)
PH (1) PH12017502376B1 (ar)
RU (1) RU2716595C2 (ar)
SA (1) SA517390602B1 (ar)
SG (1) SG10201913274VA (ar)
SV (1) SV2017005603A (ar)
TW (2) TW202137985A (ar)
UY (1) UY36761A (ar)
WO (1) WO2017003120A1 (ar)
ZA (1) ZA201708429B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법
ES2955368T3 (es) * 2020-04-24 2023-11-30 Dr Falk Pharma Gmbh Formulación sistémica de un derivado de la piridinona para la enfermedad celíaca
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
EP4193987A4 (en) * 2020-08-06 2024-08-21 SK Biopharmaceuticals Co., Ltd. SOLID ORAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND PROCESS FOR ITS PREPARATION
MX2023003933A (es) 2020-10-07 2023-07-05 Athenex Inc Derivados de acetamido-feniltetrazol y métodos para utilizar los mismos.
US20250073205A1 (en) * 2020-12-18 2025-03-06 Daewoong Pharmaceutical Co., Ltd. Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
JP2022174508A (ja) * 2021-05-11 2022-11-24 花王株式会社 顆粒の製造方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JP2002518332A (ja) 1998-06-18 2002-06-25 ジョージワシントン大学 副作用低減を伴う癌治療のためのカンプトテシン化合物の投与方法
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP2002154963A (ja) * 2000-11-14 2002-05-28 Yakult Honsha Co Ltd 徐放性抗腫瘍剤
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
DE60314378T2 (de) * 2002-03-01 2008-02-28 Pfizer Italia S.R.L. Kristalline polymorphe form von irinotecanhydrochlorid
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (ja) * 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar
ES2534853T3 (es) * 2004-10-01 2015-04-29 Kabushiki Kaisha Yakult Honsha Sal de adición de ácido de irinotecán
ES2755273T3 (es) 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
CN101283983A (zh) 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
US7880591B2 (en) 2008-02-01 2011-02-01 Apple Inc. Consumer abuse detection system and method
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
SG11201503688SA (en) * 2012-11-30 2015-06-29 Glaxosmithkline Llc Novel pharmaceutical composition
CN110946836A (zh) * 2014-01-17 2020-04-03 昂科拉制药有限公司 用于治疗癌症的伊立替康的固体口服剂型
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법

Also Published As

Publication number Publication date
GT201700280A (es) 2019-10-10
CL2017003437A1 (es) 2018-06-22
MY191297A (en) 2022-06-14
SG10201913274VA (en) 2020-03-30
TW201713339A (zh) 2017-04-16
PE20181040A1 (es) 2018-07-03
ECSP17085443A (es) 2018-01-31
RU2017143849A3 (ar) 2019-09-25
DOP2017000307A (es) 2018-03-15
BR112017028468B1 (pt) 2023-03-28
MX381735B (es) 2025-03-13
ZA201708429B (en) 2019-06-26
RU2716595C2 (ru) 2020-03-13
SV2017005603A (es) 2018-03-12
PH12017502376A1 (en) 2018-06-25
US11090299B2 (en) 2021-08-17
ES2930663T3 (es) 2022-12-20
AR105203A1 (es) 2017-09-13
CR20170604A (es) 2018-04-27
MX2017014994A (es) 2018-08-15
EP3300483A4 (en) 2018-12-12
KR20170003143A (ko) 2017-01-09
US20210330666A1 (en) 2021-10-28
PH12017502376B1 (en) 2018-06-25
TWI750125B (zh) 2021-12-21
MX2021004439A (es) 2021-05-27
HK1246656A1 (zh) 2018-09-14
WO2017003120A1 (en) 2017-01-05
KR102317664B1 (ko) 2021-10-26
TW202137985A (zh) 2021-10-16
CA2988079C (en) 2023-09-26
CA2988079A1 (en) 2017-01-05
UY36761A (es) 2016-12-30
IL256278A (en) 2018-02-28
CN107949375B (zh) 2023-04-21
AU2021204259A1 (en) 2021-07-22
SA517390602B1 (ar) 2022-11-09
AU2016286804A1 (en) 2017-11-30
NZ737238A (en) 2024-03-22
IL256278B (en) 2020-11-30
JP6835746B2 (ja) 2021-02-24
EP3300483A1 (en) 2018-04-04
RU2017143849A (ru) 2019-08-01
JP2018519279A (ja) 2018-07-19
US20180153878A1 (en) 2018-06-07
EP3300483B1 (en) 2022-11-09
BR112017028468A2 (pt) 2018-08-28
CO2017013317A2 (es) 2018-03-28
JP2021070705A (ja) 2021-05-06
KR102293907B1 (ko) 2021-08-26
AU2016286804B2 (en) 2021-03-25
CN107949375A (zh) 2018-04-20
KR20210106946A (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
JO3683B1 (ar) صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها
PH12019501639A1 (en) Jaki selective inhibitors
IL312218B2 (en) Preparations for oral administration of active ingredients
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
EA201691741A1 (ru) Фармацевтическая композиция
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EP3158998A4 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
IL283405A (en) Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12016502527A1 (en) Stabilized desmopressin
HK40101429A (zh) 用於口服的活性剂的制剂
HK40101653A (zh) 用於口服的活性剂的制剂
HK40105168A (zh) 药学化合物、其盐类、其制剂和其制备和使用方法
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
IT201700120081A1 (it) Dispositivo e metodo per la somministrazione orale di principi attivi
IN2015MU00907A (ar)